Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

Short description of key information on bioaccumulation potential result: 
1 publication ( Hoehle et al., 2009) explored the ADME characteristics of Dibromoneopentyl glycol (BMP) via both Oral and intravenous administrations.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential

Additional information

Hoehle et al. (2009) performed studies to characterize the dispositional and metabolic fate of Dibromoneopentyl glycol (BMP) after oral or intravenous administration to male F-344 rats. These studies report on the absorption, distribution, metabolism, and elimination of BMP and describe the pharmacokinetics of BMP. Additional studies were designed to determine whether repeated oral administration of BMP alters its disposition profile.

After a single oral administration of [14C]BMP (10 or 100 mg/kg) >80% of the low dose and 48% of the high dose were excreted by 12 h in the urine predominantly as a glucuronide metabolite.  After repeated daily oral doses for 5 or 10 days, route and rate of elimination were similar to those obtained after single administrations of BMP.  In all studies, the radioactivity recovered in feces was low (<15%).  The total amt. of radioactivity remaining in tissues at 72 h after a single oral administration of BMP (100 mg/kg) was less than 1% of the dose, and repeated daily dosing did not lead to retention in tissues.  After i.v. administration, the radiolabeled test material was found in blood decreased rapidly. Excretion profiles were similar to those after oral administration.  Parent BMP and BMP glucuronide were present in blood plasma after oral or i.v. dosing.  After an i.v. dose of BMP (15 mg/kg) the hepatic BMP glucuronide was primarily exported into the bile (>50% within 6 h), but it underwent enterohepatic recycling with subsequent elimination in the urine. These data indicate that the extensive excretion and rapid glucuronidation by the liver limits exposure of internal tissues to BMP by greatly reducing its systemic bioavailability after oral exposure.